Vonoprazan
(TAK-438)Phase 3Small molecule
TakedaTAK-438 is used to treat acid reflux and ulcers by reducing the amount of acid produced in the stomach. It works differently than older acid-reducing medications and may be more effective for some patients.[1] Vonoprazan is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Vonoprazan is one of 17 small molecule programs targeting Functioanl Dyspepsia. It is currently in Phase 3.
2
Indications
29
Total Trials
3
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
30 competitors in Helicobacter Pylori Infection
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Flagyl
DDePuy Orthopaedics
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Levaquin
WWim Janssens
Approved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Achromycin V
WWyeth-Lederle Vaccines
Approved
Potassium Citrate
MMission Pharmacal
Approved
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Vonoprazan
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Duodenal Ulcer8 trials
Show 5 more trials
Esophagitis4 trials
Tics3 trials
Interaction2 trials
9 more indications
Gastric Ulcer2 trials
Efficacy1 trial
Functioanl Dyspepsia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TAK-438. EMBL-EBI & Wellcome Sanger Institute.
- [4]